21:59 , Aug 21, 2019 |  BC Extra  |  Company News

Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer...
02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
00:05 , Aug 9, 2019 |  BC Innovations  |  Tools & Techniques

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...
22:27 , Jul 31, 2019 |  BC Extra  |  Preclinical News

July 31 Preclinical Quick Takes: Sangamo reveals new gene editors; plus a CRISPR prediction model and vaccine boosters for ischemia

Sangamo unveils next-gen ZFN editors  In a Nature Biotechnology study , Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported a next generation zinc finger nuclease (ZFN) gene editing technology with amino acid substitutions in the enzyme’s catalytic domain...
23:54 , Jul 26, 2019 |  BioCentury  |  Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
21:28 , Jul 19, 2019 |  BC Extra  |  Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
22:59 , Jul 18, 2019 |  BC Innovations  |  Emerging Company Profile

Neoleukin emerges with a de novo approach to improving biologics

With a platform to design proteins from scratch, Neoleukin is making a new class of biologics that resemble their endogenous protein counterparts in structure, but not in sequence. The strategy gives the company a clean...
16:37 , Jul 18, 2019 |  BC Innovations  |  Distillery Therapeutics

Great ape-derived adenovirus vaccines from Nouscom for colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Vaccination with neoantigen-encoding adenoviruses derived from great apes could help treat colorectal cancer. The neoantigens were identified by analyzing predicted MHC I and MHC II binding affinity, mutation allele...
23:21 , Jul 10, 2019 |  BC Innovations  |  Distillery Therapeutics

A hydroxypyridinone as chelation therapy for uranium exposure

DISEASE CATEGORY: Other INDICATION: Poisoning A 3,2-hydroxypyridinone could help remove uranium from kidneys and bones following exposure to the toxin. The compound, which was derived from a previously reported hydroxypyridinone-based uranium chelator, bound uranium in...
23:40 , Jul 2, 2019 |  BC Extra  |  Company News

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field. Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights...